Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Company Overview
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of novel therapeutic candidates. The company is strategically positioned in the fields of immunology, inflammation, and oncology, utilizing an asset-rich in-licensing model that leverages the deep experience of its founding team. This approach focuses on targeting high unmet needs among patient populations with conditions that are complex and challenging to manage, ensuring that Gossamer Bio remains relevant in addressing critical healthcare issues.
Core Business Areas
The company’s operations are centered on identifying and advancing therapeutic candidates that address key disease mechanisms such as cellular overgrowth, fibrosis, and dysregulated vascular remodeling. By focusing on immunology, inflammation, and oncology, Gossamer Bio develops treatments aimed at conditions including pulmonary arterial hypertension, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, specific oncology indications, and moderate-to-severe respiratory conditions such as eosinophilic asthma. Its expert research and development team capitalizes on proven methodologies in drug discovery, ensuring that each candidate is backed by comprehensive preclinical and clinical evaluation.
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) will host a public conference call and webcast on December 18, 2023, at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) granted 1,500,000 stock options to Bob Smith, the newly appointed Chief Commercial Officer, with an exercise price of $0.969 per share. The options will vest over four years, subject to Mr. Smith’s continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) appoints Bob Smith as Chief Commercial Officer, leveraging his 30 years of pharmaceutical experience, including leadership at Merck and Actelion, to drive the commercialization of seralutinib for pulmonary arterial hypertension treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) has appointed Dr. John Quisel, President and CEO of Disc Medicine, to its Board of Directors. Dr. Quisel's extensive experience in the biopharmaceutical industry and his strategic insights in the treatment of pulmonary arterial hypertension (PAH) are expected to enhance Gossamer's ability to bring seralutinib to patients. His successful track record and leadership roles at Disc Medicine and Acceleron Pharma demonstrate his expertise in building and growing biopharmaceutical companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) reports $329 million in cash, cash equivalents & marketable securities, with Phase 3 PROSERA site activations ahead of schedule and first dosing expected in 4Q23. Additional data from TORREY Open-Label Extension also expected in 4Q23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
-
Rhea-AI Summary
Gossamer Bio announces the appointment of Dr. Rainer Zimmermann as Vice President of Medical Affairs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
Rhea-AI Summary
Gossamer Bio announces positive data on seralutinib for PAH treatment at ERS Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (GOSS) to Initiate Phase 3 PROSERA Study in PAH Patients, Expects Additional Data from TORREY Open-Label Extension. $374 Million in Cash, Cash Equivalents & Marketable Securities as of June 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) announced a conference call with PAH experts to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension for the treatment of pulmonary arterial hypertension (PAH). The call will be held on Tuesday, July 25th at 10 a.m. EDT. Investors and analysts can access the live audio webcast through the company's website or via phone. The discussion will feature world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
Rhea-AI Summary
Gossamer Bio, Inc. has entered into a securities purchase agreement to sell securities in a private placement for gross proceeds of approximately $212 million. The financing includes participation from new and existing institutional investors. The company plans to use the net proceeds to fund the ongoing development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.87%
Tags
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
The current stock price of Gossamer Bio (GOSS) is $1.45 as of March 14, 2025.
What is the market cap of Gossamer Bio (GOSS)?
The market cap of Gossamer Bio (GOSS) is approximately 300.3M.
What is Gossamer Bio's core business focus?
Gossamer Bio is primarily focused on the discovery, development, and commercialization of novel therapeutic candidates. Its main areas of expertise include immunology, inflammation, and oncology, targeting conditions with high unmet medical needs.
How does Gossamer Bio generate revenue?
As a clinical-stage biopharmaceutical company, Gossamer Bio’s revenue generation is closely tied to its in-licensing strategy and the advancement of its therapeutic pipeline. The company leverages partnerships and strategic asset acquisitions to support its R&D efforts.
What therapeutic areas does the company target?
Gossamer Bio targets several critical disease areas including conditions related to pulmonary arterial hypertension, inflammatory bowel diseases, oncology indications, and inflammatory respiratory diseases. These focal areas are chosen due to unmet needs in modern therapeutic development.
How does the company differentiate itself from competitors?
Gossamer Bio differentiates itself through its asset-rich in-licensing environment and the strong execution track record of its founding team. This strategic focus on high unmet need areas and precision in targeting specific disease mechanisms sets it apart in a competitive biopharmaceutical landscape.
What is the significance of focusing on high unmet needs?
Focusing on high unmet needs allows Gossamer Bio to address diseases where current treatment options are limited or insufficient. This approach not only improves patient outcomes but also positions the company as a key player in areas where effective therapies are most urgently required.
What role does the company’s clinical-stage status play in its operations?
Being a clinical-stage company means that Gossamer Bio is primarily involved in testing new therapeutic candidates in clinical trials to assess their safety and efficacy. This stage is critical in de-risking the development process and building a robust pipeline that is essential for long-term operational success.
Gossamer Bio
Nasdaq:GOSS
GOSS Rankings
GOSS Stock Data
300.25M
219.14M
3.29%
78.27%
2.76%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO